The aims of the present study were to investigate the role of pharmacology in the design of first-in-man (FIM) trials in the Netherlands, and to evaluate the change in design approaches between 2007 and 2015.
Introduction
Good clinical practice in clinical drug trials starts with choosing the optimal design. In first in man (FIM) trials, each first administration of a dose is of interest because the response of the human body is never fully predictable. The endpoints for each dose, in the case of FIM trials pharmacokinetics (PK), pharmacodynamics (PD), or safety and tolerability, demonstrate whether investigation of additional or other doses are required to reach efficacy with acceptable hypothetical safety. Hence, dose and endpoints are two essential aspects when designing FIM trials regarding participant safety and successful clinical development [1] [2] [3] [4] [5] [6] [7] [8] .
Reports on the two major trial tragedies of the past decade acknowledged that the problems in these trials emerged from choices made in the study design, ignoring substantial risks [9] [10] [11] . Apparently, the guidelines by the Food and Drug Administration (FDA) and the European Medicines Agency [2, 4] did not provide sufficient guidance to prevent the poor design choices. As a response, approaches were proposed to rethink the classical view on phase I drug trials, and to reduce the risk of dose-related uncertainties by incorporating other dosing strategies and endpoints [1, 3, 5, [12] [13] [14] [15] [16] [17] . Proposed dose strategies included using the minimal-anticipatedbiological-effect level (MABEL) in addition to the conventional no-observed-adverse-effect level (NOAEL), consideration of interspecies PK and PD differences in addition to the allometric scales, and the abolition of irrational maximum tolerated dose (MTD) testing. Furthermore, it was advocated that traditional safety/tolerability measurements needed to be augmented by PD endpoints as much as possible, as characterization of the relationships between dose, exposure and effect may prevent dose-related harm.
Perhaps because of the scarce public availability of original trial protocols of FIM studies, only a small amount of evidence exists on the use of 'PK/PD approaches' and 'tolerability approaches' in the design of FIM trials. A pilot study on seven trial protocols from 2009 suggested that this balance is still much on the side of the tolerability approach [13] . Our objective was, therefore, to investigate the occurrence of PK/PD and tolerability approaches in FIM trials in the Netherlands, and to evaluate the changes over time.
Methods
We selected all FIM trials reviewed in 2007 and in 2015 by the Dutch Institutional Review Boards (IRBs) from the database ToetsingOnline. Use of this database ensured that all trials were included, as submission of clinical trials through this portal is mandatory by law throughout the Netherlands. We excluded trials rejected by the IRB; trials that investigated generic products, biosimilars and new formulations of older drugs; and microdosing trials. We used the IRB-approved trial protocol, investigational medicinal product dossier and investigator's brochure as the data sources for the analysis.
For each trial, we identified the design strategy for four elements: preclinical information, dose calculation, endpoints and dose escalation. In the preclinical information part, we counted the frequency and proportion of trial protocols discussing NOAEL (tolerability approach), MABEL (PK/PD approach) and information from similar compounds. In the calculation element, we counted the frequency and proportion of trials that discussed only allometric scaling without PK/PDbased justification of the applied correction factor. We also counted frequencies and proportions of trials that discussed allometric scaling overall, additional PK-guided dose adjustments (e.g. interspecies differences in metabolism) and/or additional PD-guided dose adjustments (e.g. interspecies differences in target receptor affinity) in the calculation of the first dose. Regarding the endpoints, we counted separately the frequency and proportion of trials that included safety/tolerability, PK parameters and/or PD parameters. Regarding dose escalation, we counted the frequency and proportion of dose escalation trials only guided by safety/tolerability, trials also guided by PK endpoints, and trials also guided by PD endpoints.
The frequencies and proportions of the investigated design elements were presented in Figures 1 and 2 , stratified by the year of IRB approval. Furthermore, because the FDA has published a separate guideline for oncology drug development which includes guidance on dose selection and escalation [18] , we also stratified the proportions by oncology vs. non-oncology. Many oncology drugs have a nonselective cytotoxic mechanism of action (e.g. platinum agents, alkylating agents, antimetabolites and taxanes [19] ) which may justify nonpharmacological approaches, in contrast to drugs in other disease areas.
Results
A total of 21 FIM trials were approved by the IRBs in the Netherlands in 2007, and 34 were approved in 2015. Table 1 summarizes the characteristics of the 55 FIM trials stratified by the year of approval. In 2015, the proportions of oncology FIM trials and of FIM trials investigating peptides, antibodies or advanced therapeutic medicinal products (ATMPs) were larger than in 2007. Figures 1 and 2 show the results for the four design strategy elements: preclinical information, dose calculation, endpoints and dose escalation. The results sometimes differed numerically between 2007 and 2015 for some of the measurements, but the directions and magnitudes of the differences were inconsistent. The most substantial differences were found in the dose escalation ( Figure 2 ): 11 out of 20 (55%) trials in 2007 that performed dose escalation escalated only based on safety/tolerability, compared with nine out of Table 1 Characteristics of the 55 first-in-man trials included in the analysis, stratified by year of Institutional Review Board review 
Figure 1
Approaches to the use of preclinical information and dose calculation. The figures are the numbers of trials that used the approach indicated in that box divided by the number of trials in that stratum. MABEL, minimal-anticipated-biological-effect level; NOAEL: no-observed-adverse-effect level; NOEL: no-observed-effect level (can be considered as similar to NOAEL); PAD, pharmacologically active dose (can be considered as similar to MABEL); PK, pharmacokinetic; PD, pharmacodynamic Most of the trials (52 out of 55; 95%) used allometric scaling to calculate the FIM dose. In 17 out of 55 (31%) trials, no methods other than allometric scaling were described in the protocol to calculate the FIM dose. PK-guided modelling (e.g. dose calculation based on predicted human oral absorption) was used in 37 out of 55 (67%) trials and PD-guided modelling (e.g. dose calculation based on predicted human receptor occupancy) was used in 24 out of 55 (44%) trials.
Regarding the choice of endpoints, all trials measured safety/tolerability and PK parameters. Forty-six out of 55 (84%) trials also evaluated PD parameters. Two trials did not perform dose escalation, so we evaluated this in the 53 dose escalation trials. The decision to proceed to a next dose level was always guided by safety/tolerability parameters. In addition, PK parameters were taken into account in 32 out of 53 (60%), and PD parameters in 19 out of 53 (36%) dose escalation trials. In 2007, 20 (55%) and in 2015 nine (27%) dose escalation trials escalated only based on safety/tolerability.
Discussion
Our analysis of 55 FIM trial protocols found that the PK/PD approach in FIM trials seems to have increased in the guidance of dose escalation. Using the PK/PD approach had not increased in the preclinical information, subsequent dose calculation or choice of endpoints. Oncology trials seemed to use the PK/PD approach more often in preclinical information and dose calculation, and measured PD endpoints more often compared with non-oncology trials.
The presumed increase in the PK/PD approach in dose escalation can be explained by the changing pharmaceutical pipeline, which has become increasingly populated with targeted compounds [20] . PK/PD techniques and measurements such as labelling and biomarkers may be better available for these newer classes. We expected that the PK/PD approach in the use of preclinical information and dose calculation would have been increased as well. In the aftermath of TGN1412, regulators had published several guidelines [2, 21] on the importance of using PK/PD approaches in establishing the FIM dose. It may be the case that PK/PD approaches have been compared with the conventional approach and made no difference, or that there was no PK/PD information available to use. However, in that case, both approaches should at least have been mentioned and justified in the protocol and/or in the investigator's brochure. Regarding the dose escalation, it might be the case that the escalation was guided by PK/PD before the start of the trial, through limiting the protocol-guided dose escalation cohorts by pharmacological reasoning. We did not count these escalations as being guided by PK/PD, as each dose increase in a FIM trial is in fact a new FIM trial for the new dose. The decision to progress to a next dose should therefore always be transparently explained and justified by available PK and/or PD data.
A similar proportion of the oncology trials used the conventional approaches of only NOAEL, only allometric scaling Figure 2 Endpoint and dose escalation approaches. The figures are the numbers of trials that used the approach indicated in that box divided by the number of trials in that stratum. PK, pharmacokinetic; PD, pharmacodynamic and only tolerability-guided escalation compared with nononcology trials. However, the oncology trials incorporated PD measurements (MABEL/PAD and PD endpoints) more often in the design compared with non-oncology trials. This can be explained by oncology FIM trials including patients more often than non-oncology trials, making it possible to measure clinical efficacy endpoints. Furthermore, the wave of targeted therapy in oncology has increasingly reached the clinical development stage over the past 10 years [22, 23] . Contrary to the classical chemotherapies, biomarkers and disease biology play a central role in the discovery of these targeted therapies.
The differences in drug types between 2007 and 2015 can also be explained by the increased share of oncology FIM trials due to the relative success of drug innovation in this disease area compared with other areas. The number of FIM trials testing peptides, antibodies and ATMPs increased in 2015 because the recent success in oncology drug development largely depends on tumour-targeted antibodies or proteins [23] .
Among the preclinical sources of information, the NOAEL is the most traditional, originating in the development of early cytostatic drugs in the 1960-1970s [24, 25] . In the animal-human dose translation, the NOAEL is converted according to allometric scales to the human equivalent dose (HED). The allometric scales have been developed through mathematical models predicting tissue exposure in humans based on animal data, adjusted for body surface area [26, 27] . The HED is divided by a safety factor -by default 10, but may be increased or decreased based on case-by-case justification -to arrive at the maximum recommended starting dose (MRSD). As the unintended toxic effects of nonspecific cytostatic drugs (destroying functional DNA) were pharmacologically similar to the intended effects (destroying tumour DNA) and hence predictable, preclinical toxicity was an effective method to estimate the human pharmacological window. However, there are two problems with this approach. First, interspecies differences in absorption, target homology, target expression and metabolism can make the extrapolation of animal toxicity completely irrelevant for humans [5, 14, 16] . The second problem arises if the intended pharmacological mechanism of action of the drug is saturated at a much lower level than that at which toxicity occurs [13] . This toxicity is then most likely not to be caused by the intended pharmacological mechanism, and hence is unpredictable with regard to location, timing, mechanism and severity. In these cases, toxicity is therefore not a suitable parameter to guide dose escalation. Preliminary data suggest that a more cautious pharmacology-based escalation approach should have been followed in the BIAL-102474-trial [9] . The intended pharmacological mechanism of action was saturated at a dose 20-fold lower than the dose at which the severe adverse events occurred. Escalation could have been stopped at a much lower dose, and the death of the participant might have been prevented.
To mitigate the safety risks related to dose uncertainties in FIM trials, we advocate that FIM trials use PK/PD approaches to justify the four design elements of preclinical information, dose calculation, endpoints and dose escalation. Whether and how these approaches are used should be determined on a case-by-case basis, and also by practical issues such as the availability of relevant biochemical parameters or tissue to measure PK/PD. A specific recommendation with regard to dose escalation is that the trial protocol should detail the PK-and/or PD-based threshold up to which the dose escalation is planned (e.g. exposure below fraction x of the NOAEL, or below fraction y of target receptor saturation). Some of the investigated trial protocols described this in detail but other protocols provided no information on the escalation threshold. We were therefore unable to identify how the thresholds were established across the analysed trials.
In all cases, investigators should systematically justify approaches that are used, as well as approaches that are not used, and IRBs should require this [28] . Efforts should be made to find and validate the best possible proxy measurements in case biochemical parameters are absent. In this way, the development trajectory from drug prototypes to drug treatments may become more efficient because drugs that do not induce the postulated PK/PD effects are identified at the earliest stage possible. The current and upcoming new guidelines support our arguments [2] [3] [4] , but perhaps firmer regulatory oversight is needed to enforce further improvements.
In conclusion, PK/PD approaches to determine the first dose, endpoints and dose escalation in FIM trials are often not used, neither provide often trial protocols justification for not using them. The PK/PD approach seems to have become more common regarding dose escalation. The design choices of FIM trials differ on a case-by-case basis but trial protocols should always provide a structured justification for (not) using the PK/PD approaches.
